arginine has been researched along with liraglutide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B | 1 |
| Cullis, PR; Fidelj, V; Fricker, G; Grundmann, C; Kleist, C; Kulkarni, JA; Leotta, K; Mier, W; Özbek, S; Roth, R; Sauter, M; Storck, P; Tursch, A; Uhl, P; Witzigmann, D | 1 |
2 trial(s) available for arginine and liraglutide
| Article | Year |
|---|---|
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Microcirculation; Middle Aged; Plasminogen Activator Inhibitor 1; Proinsulin; Prospective Studies | 2012 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastroplasty; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Prediabetic State; Young Adult | 2014 |
2 other study(ies) available for arginine and liraglutide
| Article | Year |
|---|---|
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Withholding Treatment | 2019 |
Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide.
Topics: Animals; Arginine; Caco-2 Cells; Cell Survival; Cell-Penetrating Peptides; Drug Delivery Systems; Female; Humans; Immunoglobulin M; Liraglutide; Nanoparticles; Polymers; Rats; Rats, Wistar; Solid-Phase Synthesis Techniques; Swine | 2020 |